Precision’s Alex Grosvenor will be presenting at World Pharma Pricing and Market Access Congress 2020 virtual. Don’t miss “Future Price and Market Access Considerations For Gene Therapies” on Friday, 25 September, 2020.
In this webinar, Carolyn Morgan of PRECISIONeffect moderates an expert panel exploring the challenges of commercializing a cell or gene therapy from industry trailblazers.
Join PRECISIONheor’s Jeroen Jansen, and partner David Phillippo, on Thursday, September 10th, 12:00pm EDT, as they provide an introduction to a novel method, called multilevel network meta-regression (ML-NMR). The method addresses several limitations with current methods, including synthesizing networks of any size and availability of IPD or aggregate studies, and – crucially for decision-making – producing estimates in any target population of interest.
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
Join Precision and Akara Group on Thursday, 8/6, 2020 | 12:00 PM EDT – 1:00 PM EDT for a special live, online discussion of best practices for pre-launch commercialization activities. Featuring Precision’s Brett DiNatale, learn about the latest advances in data, analytics, and technology, and understand how these latest advances can be used to improve decisions that impact GTN.
Historic unemployment rates have dramatically shifted healthcare coverage trends as a result of COVID-19. Join our upcoming live webinar on Wednesday, July 15th, 12:00 PM EDT, with PRECISIONadvisors’ Greg Gregory and Eddie Vogel, and learn we can address the impact of these shifts, and help support your teams’ ability to answer tough questions moving forward.
Precision’s Kelly Wilder will be participating in HR Life Sciences’ fire-side chat on racial justice. The event is bringing together senior HR life science innovators to cover a range of topics currently affecting HR strategy, from the global COVID-19 pandemic to the uprising against racial injustice in the United States and around the world to the return to work and teleworking.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
